Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than February 2039. The allowed claims cover MN...
This is the seventh NMPA-approved indication of TYVYT® (sintilimab injection). The first six indications of TYVYT® (sintilimab injection) are inclu...
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. jointly announced that the IND application was approved in China for t...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA)...
Other Notable Updates: New American College of Radiology® (ACR®) breast cancer screening guidelines now call for all women &mdas...
NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has received a ...
European Commission Approval of Opfolda and Commercial Launch of Pombiliti® + Opfolda® Anticipated in 3Q 2023 Upon Approval, Pombiliti + O...
The recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete r...
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today...
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...
-Virios’ IMC-1 Phase 3 Proposed Program is Considered Acceptable based on Initial FDA Feedback Pending Review of the Final Chronic Toxicology Program...
Forge Biologics, a leading manufacturer of genetic medicines, today announced that its manufacturing facility has successfully completed the audits necessa...
Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive dise...
The Centers for Disease Control and Prevention today reported 26.7 percent of people with autism spectrum disorder have "profound autism". It is the first ...
© 2024 Biopharma Boardroom. All Rights Reserved.
